Loading...

FITC anti-mouse CD8a Antibody

Pricing & Availability
Clone
53-6.7 (See other available formats)
Regulatory Status
RUO
Other Names
T8, Lyt2, Ly-2
Isotype
Rat IgG2a, κ
Ave. Rating
Submit a Review
Product Citations
publications
53-6.7_FITC_102110
C57BL/6 mouse splenocytes were stained with CD8 (clone 53-6.7) FITC (filled histogram) or rat IgG2a, κ FITC isotype control (open histogram).
  • 53-6.7_FITC_102110
    C57BL/6 mouse splenocytes were stained with CD8 (clone 53-6.7) FITC (filled histogram) or rat IgG2a, κ FITC isotype control (open histogram).
Compare all formats See FITC spectral data
Cat # Size Price Save
100705 50 µg ¥6,600
100706 500 µg ¥18,610
Description

CD8, also known as Lyt-2, Ly-2, or T8, consists of disulfide-linked α and β chains that form the α(CD8a)/β(CD8b) heterodimer and α/α homodimer. CD8a is a 34 kD protein that belongs to the immunoglobulin family. The CD8 α/β heterodimer is expressed on the surface of most thymocytes and a subset of mature TCR α/β T cells. CD8 expression on mature T cells is non-overlapping with CD4. The CD8 α/α homodimer is expressed on a subset of γ/δ TCR-bearing T cells, NK cells, intestinal intraepithelial lymphocytes, and lymphoid dendritic cells. CD8 is an antigen co-receptor on T cells that interacts with MHC class I on antigen-presenting cells or epithelial cells. CD8 promotes T cell activation through its association with the TCR complex and protein tyrosine kinase lck.

Product Details
Technical data sheet

Product Details

Verified Reactivity
Mouse
Antibody Type
Monoclonal
Host Species
Rat
Immunogen
Mouse thymus or spleen
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation
The antibody was purified by affinity chromatography, and conjugated with FITC under optimal conditions.
Concentration
0.5 mg/ml
Storage & Handling
The CD8a antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested
Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤1.0 µg per million cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.

Excitation Laser
Blue Laser (488 nm)
Application Notes

Clone 53-6.7 antibody competes with clone 5H10-1 antibody for binding to thymocytes3. The 53-6.7 antibody has been reported to block antigen presentation via MHC class I and inhibit T cell responses to IL-2. This antibody has also been used for depletion of CD8a+ cells. Additional reported applications (for the relevant formats) include: immunoprecipitation1,3, in vivo and in vitro cell depletion2,10,15, inhibition of CD8 T cell proliferation3, blocking of cytotoxicity3,4, immunohistochemical staining5,6 of acetone-fixed frozen sections and zinc-fixed paraffin-embedded sections, and spatial biology (IBEX)29,30. Clone 53-6.7 is not recommended for immunohistochemistry of formalin-fixed paraffin sections. The Ultra-LEAF™ purified antibody (Endotoxin < 0.01 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for functional assays or in vivo studies (Cat No. 100746).

Application References

(PubMed link indicates BioLegend citation)
  1. Ledbetter JA, et al. 1979. Immunol. Rev. 47:63. (IHC, IP)
  2. Hathcock KS. 1991. Current Protocols in Immunology. 3.4.1. (Deplete)
  3. Takahashi K, et al. 1992. P. Natl. Acad. Sci. USA 89:5557. (Block, IP)
  4. Ledbetter JA, et al. 1981. J. Exp. Med. 153:1503. (Block)
  5. Hata H, et al. 2004. J. Clin. Invest. 114:582. (IHC)
  6. Fan WY, et al. 2001. Exp. Biol. Med. 226:1045. (IHC)
  7. Shih FF, et al. 2006. J. Immunol. 176:3438. (FC)
  8. Kamimura D, et al. 2006. J. Immunol. 177:306.
  9. Bouwer HGA, et al. 2006. P. Natl. Acad. Sci. USA 103:5102. (FC, Deplete)
  10. Kao C, et al. 2005. Int. Immunol. 17:1607. PubMed
  11. Ko SY, et al. 2005. J. Immunol. 175:3309. (FC) PubMed
  12. Rasmussen JW, et al. 2006. Infect. Immun. 74:6590. PubMed
  13. Lee CH, et al. 2009. Clin. Cancer Res. PubMed
  14. Geiben-Lynn R, et al. 2008. Blood 112:4585. (Deplete) PubMed
  15. Kingeter LM, et al. 2008. J. Immunol. 181:6244. PubMed
  16. Guo Y, et al. 2008. Blood 112:480. PubMed
  17. Andrews DM, et al. 2008. J. Virol. 82:4931. PubMed
  18. Britschqui MR, et al. 2008. J. Immunol. 181:7681. PubMed
  19. Kenna TJ, et al. 2008. Blood 111:2091. PubMed
  20. Jordan JM, et al. 2008. Infect. Immun. 76:3717. PubMed
  21. Todd DJ, et al. 2009. J. Exp. Med. 206:2151. PubMed
  22. Bankoti J, et al. 2010. Toxicol. Sci. 115:422. (FC) PubMed
  23. Medyouf H, et al. 2010. Blood 115:1175. PubMed
  24. Riedl P, et al. 2009. J. Immunol. 183:370. PubMed
  25. Apte SH, et al. 2010. J. Immunol. 185:998. PubMed
  26. Bankoti J, et al. 2010. Toxicol. Sci. 115:422. (FC) PubMed
  27. del Rio ML, et al. 2011. Transpl. Int. 24:501. (FC) PubMed
  28. Cui L, et al. 2015. J Control Release. 206:220. PubMed
  29. Radtke AJ, et al. 2020. Proc Natl Acad Sci U S A. 117:33455-65. (SB) PubMed
  30. Radtke AJ, et al. 2022. Nat Protoc. 17:378-401. (SB) PubMed
Product Citations
  1. Xiang G, et al. 2022. Cell Death Dis. 13:451. PubMed
  2. Milanovic M, et al. 2021. Cancer Res. 81:426. PubMed
  3. Aimaitijiang A, et al. 2022. Genes Cells. 27:25. PubMed
  4. Chakraborty P, et al. 2022. Cancer Res. 82:1969. PubMed
  5. Martin-Martin I, et al. 2022. Cell Rep. 39:110648. PubMed
  6. Corral D, et al. 2022. Cell Rep. 39:110715. PubMed
  7. Lu R, et al. 2022. Scand J Immunol. 96:e13177. PubMed
  8. Chowdhury S, et al. 2022. Cancer Res. 82:2640. PubMed
  9. Tessaro FHG, et al. 2022. Cell Rep. 39:110977. PubMed
  10. Liu W, et al. 2022. Biomedicines. 10: . PubMed
  11. Deng P, et al. 2022. J Clin Invest. 132: . PubMed
  12. Sun Y, et al. 2023. Bioact Mater. 22:47. PubMed
  13. Li J, et al. 2022. Front Immunol. 13:1043484. PubMed
  14. Roy S, et al. 2022. Am J Cancer Res. 12:4977. PubMed
  15. Weng S, et al. 2022. Front Immunol. 13:1025931. PubMed
  16. Ding L, et al. 2023. J Clin Invest. 133: . PubMed
  17. Choi H, et al. 2023. J Nanobiotechnology. 21:5. PubMed
  18. Wang L, et al. 2022. Nutrients. 15: . PubMed
  19. Zhang B, et al. 2023. Signal Transduct Target Ther. 8:28. PubMed
  20. Elliot TAE, et al. 2022. Discov Immunol. 1:kyac009. PubMed
  21. Kemna J, et al. 2023. Nat Immunol. 24:414. PubMed
  22. Wang J, et al. 2023. Inflamm Regen. 43:12. PubMed
  23. Scherer S, et al. 2023. Nat Immunol. 24:501. PubMed
  24. Milanovic M, et al. 2021. J Immunol. 206:1228. PubMed
  25. Dragan M, et al. 2022. J Invest Dermatol. 142:583. PubMed
  26. Wei J, et al. 2022. Cancer Prev Res (Phila). 15:285. PubMed
  27. Shen JZ, et al. 2022. Mol Cell. 82:1123. PubMed
  28. Friedman D, et al. 2022. J Immunol. 208:1845. PubMed
  29. Lee KM, et al. 2022. Cancer Immunol Res. 10:829. PubMed
  30. Puth S, et al. 2022. Biomaterials. 286:121542. PubMed
  31. Alghamri MS, et al. 2022. ACS Nano. 16:8729. PubMed
  32. Edwards KJ, et al. 2022. Cancer Immunol Res. 10:1084. PubMed
  33. Akhtar MN, et al. 2022. MBio. 13:e0330921. PubMed
  34. Konjar S, et al. 2022. Proc Natl Acad Sci U S A. 119:e2202144119. PubMed
  35. Pan Y, et al. 2023. Adv Sci (Weinh). 10:e2206792. PubMed
  36. Ma X, et al. 2023. Nat Commun. 14:1606. PubMed
  37. Zhuang WR, et al. 2023. Nat Commun. 14:1675. PubMed
  38. Li D, et al. 2023. Ann Med. 55:2189295. PubMed
  39. Bhatia V, et al. 2023. Nat Commun. 14:2041. PubMed
  40. Chen F, et al. 2023. Acta Biomater. 164:387. PubMed
  41. Li Y, et al. 2023. Front Cell Infect Microbiol. 13:1117230. PubMed
  42. Wang K, et al. 2023. Nat Commun. 14:2950. PubMed
  43. Xie J, et al. 2023. Mol Ther Oncolytics. 29:61. PubMed
  44. Park HJ, et al. 2023. NPJ Vaccines. 8:84. PubMed
  45. Seo YB, et al. 2023. Int J Mol Sci. 24:. PubMed
  46. Pagano G, et al. 2023. Haematologica. . PubMed
  47. Wu MJ, et al. 2022. Cancer Discov. 12:812. PubMed
  48. Yao RQ, et al. 2022. Theranostics. 12:4606. PubMed
  49. Logan K Smith et al. 2018. Immunity. 48(2):299-312 . PubMed
  50. Liu J, et al. 2019. Immunity. 50:600. PubMed
  51. Strickley JD, et al. 2019. Nature. 575:519. PubMed
  52. Dong MB, et al. 2020. Cell. 178(5):1189-1204.e23.. PubMed
  53. Sun L, et al. 2021. Cancer Cell. 39:1361. PubMed
  54. Petrova T, et al. 2020. Sci Rep. 10:3479. PubMed
  55. Taddeo A, et al. 2022. NPJ Vaccines. 7:82. PubMed
  56. Schönberger K, et al. 2022. Cell Stem Cell. 29:131. PubMed
  57. Liu W, et al. 2020. Mol Ther Oncolytics. 17:350. PubMed
  58. Lin W, et al. 2020. Theranostics. 10:4871. PubMed
  59. Yang H, et al. 2019. Mol Metab. 23:24. PubMed
  60. Gerwing M, et al. 2020. Mol Imaging Biol. 1.959027778. PubMed
  61. Han X, et al. 2017. Int J Mol Sci. 10.3390/ijms18050942. PubMed
  62. Furuta Y, et al. 2017. PLoS One. 12(2):e0172509. PubMed
  63. Kawano H, et al. 2016. Int Immunol. 28: 489 - 501. PubMed
  64. Zhang J, et al. 2021. MedComm (Beijing). 2:256. PubMed
  65. Ren S, et al. 2019. Oncol Rep. 41:1509. PubMed
  66. Lee H, et al. 2020. Cell Metabolism. 31(4):822-836. PubMed
  67. Paschall A, et al. 2015. J Immunol. 194: 2369-2379. PubMed
  68. Zhang Y, et al. 2020. Oncol Lett. 1.053472222. PubMed
  69. Seo YB, et al. 2021. Vaccines (Basel). 9: . PubMed
  70. Greenberg J, et al. 2022. JCI Insight. Online ahead of print. PubMed
  71. Mayer RL, et al. 2022. Nat Commun. 13:6075. PubMed
  72. Yang X, et al. 2020. Blood Sci. 2:89. PubMed
  73. Wang Q, et al. 2020. Wound Repair Regen. 28:105. PubMed
  74. Castellanos CA, et al. 2021. Sci Immunol. 6:eabh0707. PubMed
  75. Apte S, et al. 2010. J Immunol. 185:998. PubMed
  76. Gotoh K et al. 2018. Cell reports. 25(7):1800-1815 . PubMed
  77. Altshuler A, et al. 2021. Cell Stem Cell. 28(7):1248-1261.e8. PubMed
  78. Delacher M, et al. 2021. Immunity. 54(4):702-720.e17. PubMed
  79. Hao B, et al. 2015. J Exp Med. 212:809. PubMed
  80. Shi S, et al. 2020. Clin Cancer Res. 26:5990. PubMed
  81. Wang Y, et al. 2022. Acta Pharm Sin B. 12:262. PubMed
  82. Wu K, et al. 2021. Aging (Albany NY). 13:. PubMed
  83. Mukherjee D, et al. 2022. Nat Commun. 13:3747. PubMed
  84. Xiong A, et al. 2022. EBioMedicine. 83:104239. PubMed
  85. Tu X, et al. 2022. Nat Commun. 13:6977. PubMed
  86. Antonia O Cuff et al. 2017. Wellcome open research. 2:39 . PubMed
  87. Pham THM, et al. 2020. Cell Host & Microbe. 27(1):54-67.e5.. PubMed
  88. Treger RS, et al. 2020. Immunity. 50(2):334-347.e9.. PubMed
  89. Morales D, et al. 2015. J Virol. 89:337. PubMed
  90. Wang Y, et al. 2016. Sci Rep. 6:31881. PubMed
  91. Lutes LK, et al. 2021. eLife. 10:00. PubMed
  92. Okamoto T, et al. 2020. Cancer Res. 3580:80. PubMed
  93. Wang X, et al. 2021. Front Cell Dev Biol. 632805:9. PubMed
  94. Luff DH, et al. 2021. Front Immunol. 631271:12. PubMed
  95. Brooks JF, et al. 2020. Cytotherapy. 22:436. PubMed
  96. Yoon Y, et al. 2021. Cancers (Basel). 13: . PubMed
  97. Dodagatta-Marri E, et al. 2021. Cell Rep. 36:109309. PubMed
  98. Suah AN, et al. 2021. J Clin Invest. 131:. PubMed
  99. Uchimura T et al. 2018. Immunity. 49(6):1049-1061 . PubMed
  100. Cousin N, et al. 2021. Cancer Res. 81:4133. PubMed
  101. Magod P, et al. 2021. Cell Reports. 36(5):109480. PubMed
  102. Mitchell JE, et al. 2021. Cell Reports. 35(2):108966. PubMed
  103. Lv H, et al. 2020. Cell Metabolism. 33(1):110-127.e5. PubMed
  104. Artinger K, et al. 2015. PLoS One. 10: 0135087. PubMed
  105. Shade K, et al. 2015. J Exp Med. 212:457. PubMed
  106. DeBerge M, et al. 2013. PLoS One. 8:79340. PubMed
  107. MacDonald A, et al. 2021. Front Immunol. 12:755995. PubMed
  108. Zebley CC, et al. 2021. Cell Rep. 37:109796. PubMed
  109. Yu Y, et al. 2022. Nat Commun. 13:6357. PubMed
  110. Zhang F, et al. 2019. Immunity. 50:738. PubMed
  111. Nicolay N, et al. 2016. Sci Rep. 6: 26645. PubMed
  112. Velázquez K, et al. 2016. Am J Physiol Gastrointest Liver Physiol. 311: G699 - G712. PubMed
  113. Wang F, et al. 2021. Cell Mol Gastroenterol Hepatol. 13:257. PubMed
  114. Wu L, et al. 2022. Theranostics. 12:842. PubMed
  115. Gu Y, et al. 2021. Cell Res. Online ahead of print. PubMed
  116. Maluski M, et al. 2019. J Clin Invest. 129:5108. PubMed
  117. Xiao P, et al. 2019. J Exp Med. 216:337. PubMed
  118. Topper MJ et al. 2017. Cell. 171(6):1284-1300 . PubMed
  119. Li Y, et al. 2019. Sci Rep. 9:6932. PubMed
  120. Zhang B, et al. 2021. Nat Biomed Eng. 5:1288. PubMed
  121. Wu J, et al. 2020. Immunity. 53:115. PubMed
  122. Köchl R, et al. 2020. Elife. 9:00. PubMed
  123. Len-Letelier RA, et al. 2020. Frontiers in Immunology. 11:583382. PubMed
  124. Pishesha N, et al. 2021. Proc Natl Acad Sci U S A. 118:. PubMed
  125. Webster P, et al. 2018. Nat Commun. 9:2649. PubMed
  126. Niemann J, et al. 2019. Nat Commun. 10:3236. PubMed
  127. Srivastava S, et al. 2019. Cancer Cell. 35:489. PubMed
  128. Aebischer D, et al. 2014. PLoS One. 9:99297. PubMed
  129. Drees J, et al. 2015. Anticancer Res. 35:843. PubMed
  130. Lu X, et al. 2016. Nat Commun. 7: 12719. PubMed
  131. Xie Z, et al. 2020. Light Sci Appl. 0.486805556. PubMed
  132. Li Y, et al. 2020. Cell Stem Cell. 27(5):732-747.e7. PubMed
  133. Crowe JL, et al. 2020. Proc Natl Acad Sci U S A. 22953:117. PubMed
  134. Wu Y, et al. 2021. Nat Commun. 12:2346. PubMed
  135. Ren Y, et al. 2022. J Immunother Cancer. 10:. PubMed
  136. Wan X, et al. 2018. Nature. 560:107. PubMed
  137. Qi S et al. 2016. eLife. 5 pii: e14756. PubMed
  138. Budida R, et al. 2017. Eur J Immunol. 47:1819. PubMed
  139. Kim JH, et al. 2019. Mol Med. 25:33. PubMed
  140. Volberding PJ, et al. 2021. Cell Reports. 35(8):109160. PubMed
  141. Tacconi C, et al. 2021. Cell Reports. 35(2):108993. PubMed
  142. Yang J, et al. 2020. Nature. 586:572. PubMed
  143. Knocke S, et al. 2016. Cell Rep. 17:2234-2246. PubMed
  144. Ito C, et al. 2015. PLoS One. 10: e0140808. PubMed
  145. Wu S, et al. 2014. Clin Vaccine Immunol. 21:156. PubMed
  146. Bosnjak B, et al. 2021. Front Immunol. 12:772240. PubMed
  147. Sun C, et al. 2022. J Adv Res. 35:71. PubMed
  148. Dey S, et al. 2020. J Immunother Cancer. 8:. PubMed
  149. Zheng D, et al. 2022. Acta Pharm Sin B. 12:2740. PubMed
  150. Liu B, et al. 2022. Mol Med Rep. 26:. PubMed
  151. Nikolos F, et al. 2022. Nat Commun. 13:1487. PubMed
  152. Fang Y, et al. 2019. Aging (Albany NY). 11:4910. PubMed
  153. Horkova V, et al. 2020. Cell Reports. 30(5):1504-1514.e7.. PubMed
  154. Du J, et al. 2018. AMB Express. 8:158. PubMed
  155. Holman P, et al. 2005. J Immunol. 174:3986. PubMed
  156. Trefzer A, et al. 2021. Cell Reports. 34(6):108748. PubMed
  157. Vaena S, et al. 2021. Cell Reports. 35(5):109076. PubMed
  158. Huang Z, et al. 2021. Nat Commun. 12:145. PubMed
  159. Grioni M, et al. 2021. Blood Adv. 5:2817. PubMed
  160. Matundan HH, et al. 2021. J Virol. 95:e0103621. PubMed
  161. Wang R, et al. 2022. Front Immunol. 13:947756. PubMed
  162. Jin C, et al. 2022. Oncoimmunology. 11:2099642. PubMed
  163. Frost JN, et al. 2021. Med (N Y). 2:164. PubMed
  164. Daneshmandi S, et al. 2021. Elife. 10:. PubMed
  165. Huang L, et al. 2021. Breast Cancer Res Treat. Online ahead of print. PubMed
  166. Denny JE, et al. 2019. Sci Rep. 2.786111111. PubMed
  167. Landon J Edgar et al. 2018. Cell chemical biology. 26(1):131-136 . PubMed
  168. Chatterjee S et al. 2017. Cell metabolism. 27(1):85-100 . PubMed
  169. Yan J, et al. 2020. Cell Rep. 107820:31. PubMed
  170. Yi W, et al. 2021. Cell Reports. 34(13):108922. PubMed
  171. Shen JZ, et al. 2020. Cell. 184(2):352-369.e23. PubMed
  172. Li X, et al. 2020. Nat Commun. 4.877777778. PubMed
  173. Zhan L, et al. 2022. Cancer Lett. 529:37. PubMed
  174. Tsukui H, et al. 2020. BMC Cancer. 20:411. PubMed
  175. Blagih J, et al. 2020. Cell Rep. 30:481. PubMed
  176. Fu S, et al. 2020. Nat Commun. 0.7625. PubMed
  177. Tao Z, et al. 2019. Clin Cancer Res. 25:1113. PubMed
  178. Zhang NN, et al. 2020. Cell. 182(5):1271-1283. PubMed
  179. Bartolacci C, et al. 2018. Cancer Immunol Res. 1.281944444. PubMed
  180. Riedl P, et al. 2009. J Immunol. 183:370. PubMed
  181. Wang L, et al. 2015. Cancer Immunol Res. 3: 1030-1041. PubMed
  182. Li Y, Kaneda T 2016. Sci Rep. 6: 25077. PubMed
  183. Perry JL, et al. 2020. ACS Nano. 5.583333333. PubMed
  184. Feng D, et al. 2022. Nat Commun. 13:5554. PubMed
  185. He C, et al. 2022. Nat Commun. 13:5459. PubMed
  186. Li M, et al. 2021. Cancers (Basel). 13:. PubMed
  187. Berghoff SA, et al. 2021. Nat Neurosci. 24:47. PubMed
  188. Fang F, et al. 2021. Cell Rep. 37:109981. PubMed
  189. Dulken BW, et al. 2019. Nature. 571:205. PubMed
  190. Hu Z, et al. 2020. PLoS One. 15:e0228339. PubMed
  191. Ibrahim ML, et al. 2018. Cell Rep. 25:3036. PubMed
  192. Chen R, et al. 2021. Cell Reports. 34(7):108751. PubMed
  193. Kvell K, et al. 2014. Immunobiology. 219:644. PubMed
  194. Wu P, et al. 2020. Cancer Immunol Res. 8:1470. PubMed
  195. Soria-Castro R, et al. 2020. Sci Rep. 10:17802. PubMed
  196. Xia Y, et al. 2018. Cell. 175:1059. PubMed
  197. Urata S, et al. 2018. PLoS Pathog. 14:e1007172. PubMed
  198. Raju S, et al. 2020. Cell Reports. 29(9):2556-2564.e3.. PubMed
  199. Panigrahy D, et al. 2019. J Clin Invest. 130:2964. PubMed
  200. Shen L, et al. 2015. Cancer Immunol Res. 3:136. PubMed
  201. Calderon B, et al. 2015. J Exp Med. 212: 1497-1512. PubMed
  202. Yasuma K, et al. 2016. PLoS Pathog. 12: 1005372. PubMed
  203. Martina M, et al. 2016. J Am Soc Nephrol. 27: 1113-1123. PubMed
  204. Miura N, et al. 2017. Mol Ther. 10.1016/j.ymthe.2017.01.020. PubMed
  205. Daneshmandi S, et al. 2021. Cell Reports. 34(10):108831. PubMed
  206. Li Q, et al. 2022. Front Oncol. 12:841977. PubMed
  207. Kung YJ, et al. 2022. J Biomed Sci. 29:57. PubMed
  208. Leary N, et al. 2022. J Extracell Vesicles. 11:e12197. PubMed
  209. Kos S, et al. 2019. PLoS One. 14:e0217762. PubMed
  210. Ren Y, et al. 2021. Nat Commun. 12:5405. PubMed
  211. Roderick J, et al. 2014. Proc Natl Acad Sci U S A. 111:14436. PubMed
  212. Kim S, et al. 2022. Cancers (Basel). 14:. PubMed
  213. Zhang Z, et al. 2020. Nature. 579:415. PubMed
  214. Cané S, et al. 2021. J Immunother Cancer. 9:. PubMed
  215. Porrello A, et al. 2018. Nat Commun. 9:1988. PubMed
  216. Sade–Feldman M, et al. 2018. Cell. 175:998. PubMed
  217. Golan K et al. 2018. Cell stem cell. 23(4):572-585 . PubMed
  218. Sivapatham S, et al. 2019. Front Immunol. 1.865277778. PubMed
  219. Royzman D, et al. 2019. Front Immunol. 10:633. PubMed
  220. Tsyklauri O, et al. 2021. EMBO Rep. 22:e50785. PubMed
  221. Petriv N, et al. 2021. Oncoimmunology. 10:1874159. PubMed
  222. Chryplewicz A, et al. 2022. Cancer Cell. 40:1111. PubMed
  223. Li X, et al. 2022. Oncoimmunology. 11:2118210. PubMed
  224. Li H, et al. 2022. iScience. 25:104481. PubMed
  225. Wang X, et al. 2022. Elife. 11:. PubMed
  226. Chakraborty P, et al. 2020. Cell Reports. 28(7):1879-1893.e7.. PubMed
  227. Fleskens V, et al. 2019. Cell Rep. 26:3600. PubMed
  228. Li K, et al. 2020. Nat Commun. 0.795138889. PubMed
  229. Burton OT, et al. 2018. Clin Exp Allergy. 48:288. PubMed
  230. Su M, et al. 2018. Immunol Cell Biol. 9:2448. PubMed
  231. Hebbandi Nanjundappa R, et al. 2017. Cell. 171:655. PubMed
  232. Tanegashima K et al. 2017. EBioMedicine. 24:247-256 . PubMed
  233. Hong Y, et al. 2019. J Extracell Vesicles. 8:1670893. PubMed
  234. Kim YS, et al. 2018. Front Immunol. 9:1093. PubMed
  235. D'Cruz L, et al. 2014. J Immunol. 192:2227. PubMed
  236. Katsuyama T, et al. 2021. Cell Reports. 36(1):109339. PubMed
  237. Wu L, et al. 2020. Cancer Immunol Res. 710:8. PubMed
  238. Wen X, et al. 2021. World J Gastroenterol. 27:2834. PubMed
  239. Wang K, et al. 2021. Nat Commun. 12:4558. PubMed
  240. Li CY, et al. 2022. Int J Mol Sci. 23:. PubMed
  241. Ying B, et al. 2022. Sci Transl Med. 14:eabm3302. PubMed
  242. Lee S, et al. 2021. Autophagy. 18:1062. PubMed
  243. Song X, et al. 2022. Transl Oncol. 15:101306. PubMed
  244. Akhtar MN, et al. 2020. PLoS Pathog. 16:e1009136. PubMed
  245. Zhi Y, et al. 2020. Int J Mol Med. 45:1327. PubMed
  246. Bing Wu et al. 2018. Immunity. 49(5):886-898 . PubMed
  247. Xie Z, et al. 2020. Light Sci Appl. 9:161. PubMed
  248. Gu Z, et al. 2021. Nat Genet. 53:672. PubMed
  249. Yang F, et al. 2021. Nat Commun. 12:3424. PubMed
  250. Xie L, et al. 2020. Infect Immun. :88. PubMed
  251. Hayashi K, et al. 2020. Nat Commun. 4.832638889. PubMed
  252. Schlecker E, et al. 2012. J Immunol. 189:5602. PubMed
RRID
AB_312744 (BioLegend Cat. No. 100705)
AB_312745 (BioLegend Cat. No. 100706)

Antigen Details

Structure
Ig superfamily, CD8α chain, 34 kD
Distribution

Most thymocytes, T cell subset, some NK cells, lymphoid dendritic cells

Function
Co-receptor for TCR
Ligand/Receptor
MHC class I molecule
Antigen References

1. Barclay A, et al. 1997. The Leukocyte Antigen FactsBook Academic Press.
2. Zamoyska R. 1994. Immunity 1:243.
3. Ellmeier W, et al. 1999. Annu. Rev. Immunol. 17:523.

Gene ID
12525 View all products for this Gene ID
UniProt
View information about CD8alpha on UniProt.org

Related FAQs

There are no FAQs for this product.

Other Formats

View All CD8a Reagents Request Custom Conjugation
Description Clone Applications
APC anti-mouse CD8a 53-6.7 FC
Biotin anti-mouse CD8a 53-6.7 FC,IHC
FITC anti-mouse CD8a 53-6.7 FC
PE anti-mouse CD8a 53-6.7 FC
PE/Cyanine5 anti-mouse CD8a 53-6.7 FC
Purified anti-mouse CD8a 53-6.7 FC,CyTOF®,IHC-F,IP
PE/Cyanine7 anti-mouse CD8a 53-6.7 FC
PE/Dazzle™ 594 anti-mouse CD8a 53-6.7 FC
APC/Fire™ 750 anti-mouse CD8a 53-6.7 FC
GoInVivo™ Purified anti-mouse CD8a 53-6.7 FC
TotalSeq™-A0002 anti-mouse CD8a 53-6.7 PG
Spark Blue™ 550 anti-mouse CD8a 53-6.7 FC
Spark NIR™ 685 anti-mouse CD8a 53-6.7 FC
TotalSeq™-B0002 anti-mouse CD8a 53-6.7 PG
Spark YG™ 570 anti-mouse CD8a 53-6.7 IHC-F
TotalSeq™-C0002 anti-mouse CD8a 53-6.7 PG
PE/Fire™ 640 anti-mouse CD8a 53-6.7 FC
PE/Fire™ 700 anti-mouse CD8a 53-6.7 FC
APC/Cyanine7 anti-mouse CD8a 53-6.7 FC
Alexa Fluor® 488 anti-mouse CD8a 53-6.7 FC,3D IHC
Alexa Fluor® 647 anti-mouse CD8a 53-6.7 FC,IHC-F,3D IHC,SB
Pacific Blue™ anti-mouse CD8a 53-6.7 FC
Alexa Fluor® 700 anti-mouse CD8a 53-6.7 FC
PerCP/Cyanine5.5 anti-mouse CD8a 53-6.7 FC
PerCP anti-mouse CD8a 53-6.7 FC
Brilliant Violet 421™ anti-mouse CD8a 53-6.7 FC,IHC,SB
Brilliant Violet 570™ anti-mouse CD8a 53-6.7 FC
Brilliant Violet 650™ anti-mouse CD8a 53-6.7 FC
Brilliant Violet 605™ anti-mouse CD8a 53-6.7 FC
Ultra-LEAF™ Purified anti-mouse CD8a 53-6.7 FC,CyTOF®,IHC,IP,Depletion,Block
Brilliant Violet 711™ anti-mouse CD8a 53-6.7 FC
Brilliant Violet 785™ anti-mouse CD8a 53-6.7 FC
Brilliant Violet 510™ anti-mouse CD8a 53-6.7 FC
Purified anti-mouse CD8a (Maxpar® Ready) 53-6.7 FC,CyTOF®
Alexa Fluor® 594 anti-mouse CD8a 53-6.7 IHC-F,FC,3D IHC
Spark Blue™ 574 anti-mouse CD8a Antibody 53-6.7 FC
Spark Violet™ 423 anti-mouse CD8a Antibody 53-6.7 FC
Spark UV™ 387 anti-mouse CD8a 53-6.7 FC
Spark Blue™ 515 anti-mouse CD8a 53-6.7 FC
APC/Fire™ 810 anti-mouse CD8a 53-6.7 FC
Spark Red™ 718 anti-mouse CD8a (Flexi-Fluor™) 53-6.7 FC
PE/Fire™ 810 anti-mouse CD8a 53-6.7 FC
Spark PLUS UV395™ anti-mouse CD8a 53-6.7 FC
PerCP/Fire™ 780 anti-mouse CD8a 53-6.7 FC
Spark YG™ 581 anti-mouse CD8a (Flexi-Fluor™) 53-6.7 FC
Spark YG™ 593 anti-mouse CD8a (Flexi-Fluor™) Antibody 53-6.7 FC
StarBright UltraViolet 575 anti-mouse CD8a 53-6.7 FC
Spark PLUS V475™ anti-mouse CD8a 53-6.7 FC
StarBright UltraViolet 795 anti-mouse CD8a 53-6.7 FC
Go To Top Version: 2    Revision Date: 01/21/2014

For Research Use Only. Not for diagnostic or therapeutic use.

 

This product is supplied subject to the terms and conditions, including the limited license, located at www.biolegend.com/terms) ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.

 

BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

ProductsHere
Login / Register
Remember me
Forgot your password? Reset password?
Create an Account